The record on rosiglitazone and the risk of myocardial infarction

New England Journal of Medicine

Volumn 357, Issue 1, 2007, Pages 67-69

  Psaty, Bruce M ^a,b   Furberg, Curt D ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GLIBENCLAMIDE PLUS METFORMIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE CONTROL; DRUG SAFETY; EDITORIAL; FOLLOW UP; HAZARD RATIO; HEALTH HAZARD; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MEDICAL CARE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PUBLIC HEALTH; RISK BENEFIT ANALYSIS;

EID: 34250828630     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe078116     Document Type: Editorial

References (21)

1. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
3. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
4. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials. JAMA 2003;289:2554-9.
5. Ferreira-González I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97. [Errata, JAMA 2003;289:178, 2004;291:2196.]
7. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36.
8. Atherosclerosis Risk in Communities (ARIC). Average annual incidence rate table. Chapel Hill: University of North Carolina School of Public Health. (Accessed June 14, 2007, at http://www.cscc.unc.edu/aric/othdocs/ UNLICOMMAverageAnnualIncidenceRateTables12162003.pdf.)
9. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. [Erratum, N Engl J Med 2007;356:1387-8.]
10. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105. [Erratum, Lancet 2006;368:1770.]
11. Krall RL. Cardiovascular safety of rosiglitazone. Lancet (DOI: 10.1016/S9140-6736(07)60824-1).
12. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4.
13. Montori VM, Isley WL, Guyatt GH. Waking up from the DREAM of preventing diabetes with drugs. BMJ 2007;334:882-4.
14. Psaty BM, Weiss NS, Furberg CD. Recent trials in hypertension: compelling science or commercial speech? JAMA 2006;295:1704-6.
15. Psaty BM, Weiss NS, Furberg CD, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90.
16. Wood AJJ. A proposal for radical changes in the drug-approval process. N Engl J Med 2006;355:618-23. [Erratum, N Engl J Med 2006;355:2712.]
17. Committee on the Assessment of the US Drug Safety System, Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2006.
18. Psaty BM, Burke SP. Protecting the health of the public - Institute of Medicine recommendations on drug safety. N Engl J Med 2006;355:1753-5.
19. GlaxoSmithKline. Study no. ZM2005/00181/01: Avandia Cardiovascular Event Modeling Project. (Accessed June 14, 2007, at http://ctr.gsk.co.uk/Summary/ Rosiglitazone/III_CVmodeling.pdf.)
20. European Medicines Agency. European public assessment report: Avandia. (Accessed June 14, 2007, at http://www.emea.europa.eu/humandocs/Humans/EPAR/ avandia/avandia.htm.)
21. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.